Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 4/20 | 0.66 |
| ▸ | PRKCB | P05771 | 3/20 | 0.66 |
| ▸ | PRKCA | P17252 | 3/20 | 0.66 |
| ▸ | PRKCG | P05129 | 2/20 | 0.66 |
| ▸ | HTR6 | P50406 | 11/20 | 0.64 |
| ▸ | HTR2A | P28223 | 3/20 | 0.64 |
| ▸ | HTR2C | P28335 | 3/20 | 0.64 |
| ▸ | HTR7 | P34969 | 3/20 | 0.64 |
| ▸ | DRD3 | P35462 | 1/20 | 0.64 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.53 |
| ▸ | CDK1 | P06493 | 1/20 | 0.53 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.53 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.53 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.49 |
| ▸ | CNR1 | P21554 | 2/20 | 0.44 |
| ▸ | CNR2 | P34972 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2982339 | 0.80 | GSK3B (1.00) | GSK3BPRKCBPRKCAPRKCGCCNB2 | |
| SCHEMBL3887023 | 0.78 | HTR6 (1.00) | GSK3BPRKCBPRKCAPRKCGHTR6 | |
| SCHEMBL3885901 | 0.77 | HTR6 (0.61) | GSK3BPRKCBPRKCAPRKCGHTR6 | |
| SCHEMBL12501163 | 0.71 | IKBKE (0.56) | GSK3BPRKCBPRKCAPRKCGHTR2C | |
| SCHEMBL3892738 | 0.71 | HTR2A (0.57) | HTR6HTR2AHTR2CHTR7DRD3 | |
| SCHEMBL13687088 | 0.71 | HTR6 (1.00) | HTR6HTR2AHTR2CHTR7DRD3 | |
| SCHEMBL13221693 | 0.70 | GSK3B (0.82) | GSK3BPRKCBPRKCAPRKCGCCNB2 | |
| Hydrochloric Acid SCHEMBL3885084 | 0.70 | HTR6 (0.98) | HTR6HTR2AHTR2CHTR7DRD3 | |
| SCHEMBL2982364 | 0.69 | GSK3B (1.00) | GSK3BPRKCBPRKCAPRKCGCCNB2 | |
| SCHEMBL4569767 | 0.65 | DYRK1A (0.50) | HTR6HTR2AHTR2CHTR7DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1509522-B1 | 1-(AMINOALKYL)-3-SULFONYLAZAINDOLES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH CORP (US) | 2007-02-28 | — | — | EP | claimed |
| US-6825212-B2 | SEROTONINE RECEPTORS ANTAGONIST; CENTRAL NERVOUS SYSTEM DISORDERS | WYETH | 2004-11-30 | — | — | US | claimed |
| US-20030236278-A1 | 1-(aminoalkyl)-3-sulfonylazaindoles as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2003-12-25 | — | — | US | claimed |
| US-7585873-B2 | antiserotonine agents; central nervous system disorders; Alzheimer's disease; 3-(Phenylthio)-1H-pyrrolo[2,3-b]pyridine | WYETH (US) | 2009-09-08 | — | — | US | disclosed |
| EP-1509522-B1 | 1-(AMINOALKYL)-3-SULFONYLAZAINDOLES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH CORP (US) | 2007-02-28 | — | — | EP | disclosed |
| US-7074792-B2 | 1-(aminoalkyl)-3-sulfonylazaindoles as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2006-07-11 | — | — | US | disclosed |
| US-20060148831-A1 | 1-(aminoalkyl)-3-sulfonylazaindoles as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2006-07-06 | — | — | US | disclosed |
| US-20050085481-A1 | 1-(aminoalkyl)-3-sulfonylazaindoles as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2005-04-21 | — | — | US | disclosed |
| US-6825212-B2 | SEROTONINE RECEPTORS ANTAGONIST; CENTRAL NERVOUS SYSTEM DISORDERS | WYETH | 2004-11-30 | — | — | US | disclosed |
| US-20030236278-A1 | 1-(aminoalkyl)-3-sulfonylazaindoles as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2003-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148831-A1 | 1-(aminoalkyl)-3-sulfonylazaindoles as 5-hydroxytryptamine-6 ligands | HTR6, HTR3B, HTR1A | GSK3B 3955/4885PRKCB 4360/4885PRKCA 4454/4885 |
| US-20050085481-A1 | 1-(aminoalkyl)-3-sulfonylazaindoles as 5-hydroxytryptamine-6 ligands | HTR6, HTR3B, HTR1A | GSK3B 3955/4885PRKCB 4360/4885PRKCA 4454/4885 |
| US-20030236278-A1 | 1-(aminoalkyl)-3-sulfonylazaindoles as 5-hydroxytryptamine-6 ligands | HTR6, HTR1A, HTR3B | GSK3B 4018/4885PRKCB 4277/4885PRKCA 4359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.